share_log

東陽光長江藥業：截至二零二四年六月三十日止六個月的中期業績公告

HEC CJ PHARM: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 30 08:30

Summary by Moomoo AI

宜昌東陽光長江藥業股份有限公司（「本公司」）公布截至2024年6月30日止六個月的中期業績。期內，公司營業額為人民幣2,454.8百萬元，較上年同期減少23.5%。毛利為人民幣1,949.2百萬元，下降24.0%。稅息、折舊及攤銷前溢利為人民幣1,064.2百萬元，減少33.1%。歸屬於公司權益持有人的溢利及全面收益總額為人民幣684.7百萬元，下降33.5%。每股基本及攤薄盈利均為人民幣0.78元。董事會決定不派發中期股息。公司在慢病線業務線取得顯著進展，胰島素產品營業額大幅增長140.7%，並有多款產品中標集中帶量採購。新藥線業務線磷酸依米他韋膠囊營業額增長188.5%，並成功進入國家醫保目錄。集採和新零售線業務線營業額增長60.8%，顯示公司業務管線逐漸進入收穫期。公司繼續加強內部管理，提升創新能力，致力於可持續發展。
宜昌東陽光長江藥業股份有限公司（「本公司」）公布截至2024年6月30日止六個月的中期業績。期內，公司營業額為人民幣2,454.8百萬元，較上年同期減少23.5%。毛利為人民幣1,949.2百萬元，下降24.0%。稅息、折舊及攤銷前溢利為人民幣1,064.2百萬元，減少33.1%。歸屬於公司權益持有人的溢利及全面收益總額為人民幣684.7百萬元，下降33.5%。每股基本及攤薄盈利均為人民幣0.78元。董事會決定不派發中期股息。公司在慢病線業務線取得顯著進展，胰島素產品營業額大幅增長140.7%，並有多款產品中標集中帶量採購。新藥線業務線磷酸依米他韋膠囊營業額增長188.5%，並成功進入國家醫保目錄。集採和新零售線業務線營業額增長60.8%，顯示公司業務管線逐漸進入收穫期。公司繼續加強內部管理，提升創新能力，致力於可持續發展。
Hec CJ Pharm Co., Ltd. (the Company) announces the interim business performance for the six months ended June 30, 2024. During the period, the company's operating revenue was RMB 2,454.8 million, a decrease of 23.5% compared to the same period of the previous year. The gross profit was RMB 1,949.2 million, a decrease of 24.0%. The profit before tax, depreciation, and amortization was RMB 1,064.2 million, a decrease of 33.1%. The total comprehensive income attributable to the shareholders of the Company was RMB 684.7 million, a decrease of 33.5%. Both basic and diluted earnings per share were RMB 0.78. The board of directors has decided not to distribute interim dividends. The company has made significant progress in the chronic disease business line, with a substantial growth of 140.7% in insulin product...Show More
Hec CJ Pharm Co., Ltd. (the Company) announces the interim business performance for the six months ended June 30, 2024. During the period, the company's operating revenue was RMB 2,454.8 million, a decrease of 23.5% compared to the same period of the previous year. The gross profit was RMB 1,949.2 million, a decrease of 24.0%. The profit before tax, depreciation, and amortization was RMB 1,064.2 million, a decrease of 33.1%. The total comprehensive income attributable to the shareholders of the Company was RMB 684.7 million, a decrease of 33.5%. Both basic and diluted earnings per share were RMB 0.78. The board of directors has decided not to distribute interim dividends. The company has made significant progress in the chronic disease business line, with a substantial growth of 140.7% in insulin product sales, and multiple products being successfully included in centralized volume-based procurement. The new drug business line achieved an 188.5% growth in sales of Phospholipid Emetine Capsules and has been successfully included in the national medical insurance catalog. Both the procurement and new retail business lines experienced a 60.8% growth in operating revenue, indicating that the company's business pipeline is gradually entering the harvest period. The company continues to strengthen internal management, enhance innovation capabilities, and is committed to sustainable development.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated